Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease

Further Publications Rheumatology

Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort study

Arthritis Rheumatol

Hoisnard L, Meyer A, Dray-Spira R, Weill A, Zureik M, Sbidian E

doi: 10.1002/art.42862

Further Publications Immunology

Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Ann Rheum Dis

Konzett V, Smolen JS, Nash P, Aletaha D, Winthrop K, Dörner T, Fleischmann R, Tanaka Y, Primdahl J, Baraliakos X, McInnes IB, Trauner M, Sattar N, de Wit M, Schoones JW, Kerschbaumer A

doi: 10.1016/j.ard.2025.01.023

Further Publications Immunology

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Ann Rheum Dis

Konzett V, Smolen JS, Nash P, Winthrop K, Aletaha D, Dörner T, Fleischmann R, Tanaka Y, Primdahl J, Baraliakos X, McInnes IB, Trauner M, Sattar N, de Wit M, W Schoones J, Kerschbaumer A

doi: 10.1016/j.ard.2025.01.024

Rheumatoid Arthritis

Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study

Arthritis Rheumatol

Eberhard A, Di Giuseppe D, Askling J, Bergman S, Bower H, Chatzidionysiou K, Forsblad-d'Elia H, Kastbom A, Olofsson T, Frisell T, Turesson C

doi: 10.1002/art.43014

Psoriatic ArthritisRheumatoid Arthritis

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Ann Rheum Dis

Hernández-Cruz B, Otero-Varela L, Freire-González M, Busquets-Pérez N, García González AJ, Moreno-Ramos M, Blanco-Madrigal JM, Manrique-Arija S, Perez-Pampin E, Ruiz-Montesino D, Sánchez-Alonso F, Sanchez-Piedra C, Castrejón I, BIOBADASER Study Group

doi: 10.1136/ard-2023-225271

Autoimmune Disease

Primary Cesarean delivery and future risk of maternal autoimmune disease: A population-based cohort study

J Autoimmun

Scime NV, Grandi SM, De Vera MA, Dennis CL, Boblitz A, Brown HK

doi: 10.1016/j.jaut.2025.103370

Melanoma and Skin Cancer

Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma

JAMA Dermatol

Ran NA, Granger EE, Brodland DG, Cañueto J, Carr DR, Carter JB, Carucci JA, Hirotsu KE, Koyfman SA, Mangold AR, Girardi FM, Shahwan KT, Srivastava D, Vidimos AT, Willenbrink TJ, Wysong A, Ruiz ES

doi: 10.1001/jamadermatol.2025.0128

Further Publications Rheumatology

Risk factors of COVID-19 related hospitalization of pediatric patients with rheumatic diseases: a systematic review and meta-analysis

Rheumatology (Oxford)

Zhao Q, Wallace B, Ronis T, Jung L

doi: 10.1093/rheumatology/keae664

Autoimmune DiseaseFurther Publications ImmunologyFurther Publications Rheumatology

Prevalence and Risk Factors of Post-Acute Sequela of COVID-19 in Adults with Systemic Autoimmune Rheumatic Diseases

J Rheumatol

Teles MS, Brundage J, Chiang TP, Alejo JL, Henriquez N, Wallwork R, Christopher Stine L, Massie A, Segev DL, Connolly CM, Paik JJ, Werbel WA

doi: 10.3899/jrheum.2023-1212

Related content

Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort study

Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Primary Cesarean delivery and future risk of maternal autoimmune disease: A population-based cohort study

Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma

Risk factors of COVID-19 related hospitalization of pediatric patients with rheumatic diseases: a systematic review and meta-analysis

Prevalence and Risk Factors of Post-Acute Sequela of COVID-19 in Adults with Systemic Autoimmune Rheumatic Diseases